P—gp、GST—π的表达对三阴性乳腺癌新辅助化疗疗效的预测价值(3)
![]() |
第1页 |
参见附件。
[7] Thike A A,Cheok P Y,Jara-Lazaro A R,et al.Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer[J].Mod Pathol,2010,23(1):123-133.
[8] Guo Z,Zhu J,Zhao L,et al.Expression and clinical significanceof multidrug resistance proteins in brain tumors[J].J Exp Clin Cancer Res,2010,29(11):122.
[9] Carey LA,Dees E C,Sawyer L,et al.The Triple Negative Paradox:Primary Tumor Chemosensitivity of Breast Cancer Subtypes[J].Clini Cancer Res,2007,13(8):2329-2334.
[10] Liedtke C,Mazouni C,Hess K R,et al.Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-NegativeBreast Cancer[J].J Clin Oncol,2008,26(8):1275-1281.
[11] Masuda H,Masuda N, Kodama Y,et al.Predictive factors forthe effectiveness of neoadjuvant chemotherapy and prognosis intriple-negative breast cancer patients[J].Cancer Chemoth Pharm,2011,67(4):911-917.
[12] Iwata H,Sato N,Masuda N,et al.DocetaxelFollowedbyFluorouracil/Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy forPatients with Primary Breast Cancer[J].Jpn J Clini Oncol,2011,41(7):867-875.
[13]曾娟紫,吴国武.卡培他滨在蒽环和紫杉类失败的晚期乳腺癌中疗效与安全性的分析[J].中国医学创新,2013,10(5):41-42.
[14]廖洪叶,郭巨江.乳腺癌预防性治疗的进展[J].中国医学创新,2014,11(3):147-149.
(收稿日期:2014-04-09) (编辑:韩珊珊)
您现在查看是摘要介绍页,详见PDF附件。